Literature DB >> 7681207

Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth.

S M Loop1, T A Rozanski, R C Ostenson.   

Abstract

A new human prostate tumor cell line (ALVA-31) has been established from a biopsy specimen of primary tumor obtained during prostatectomy. The cell line has been maintained for more than 48 months in stable growth. The in vitro doubling time was determined to be approximately 26 hr. The chromosome number ranged from 24-112, with a modal number of 59 tested over several time points throughout continuous culture. Karyotypic analysis of late-passaged cells demonstrated approximately 70 human chromosomes, 8-14 markers, and two X chromosomes without a Y chromosome. Prostatic origin was confirmed by the expression of both prostate specific antigen and prostatic acid phosphatase, using specific antisera and immunoradiolabelling techniques. Prostate tumor xenografts were grown in intact male, castrate male, and female athymic mice; however, the rate of tumor growth was clearly dependent upon serum testosterone levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681207     DOI: 10.1002/pros.2990220202

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy.

Authors:  Lorena A Puto; John Brognard; Tony Hunter
Journal:  J Biol Chem       Date:  2015-04-22       Impact factor: 5.157

2.  The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related.

Authors:  M A Rice; R A Ishteiwy; F Magani; T Udayakumar; T Reiner; T J Yates; P Miller; C Perez-Stable; P Rai; R Verdun; D M Dykxhoorn; K L Burnstein
Journal:  Oncogene       Date:  2016-02-22       Impact factor: 9.867

Review 3.  Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis.

Authors:  L Y Bourrguignon; N Iida; C F Welsh; D Zhu; A Krongrad; D Pasquale
Journal:  J Neurooncol       Date:  1995-12       Impact factor: 4.130

4.  Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.

Authors:  Carlo Vicentini; Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Angelo Marronaro; Mauro Bologna
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-04       Impact factor: 4.553

5.  miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer.

Authors:  Adriann M Hovey; Eric J Devor; Patrick J Breheny; Sarah L Mott; Donghai Dai; Kristina W Thiel; Kimberly K Leslie
Journal:  Transl Oncol       Date:  2015-04       Impact factor: 4.243

6.  Decellularized In Vitro Capillaries for Studies of Metastatic Tendency and Selection of Treatment.

Authors:  Outi Huttala; Desiree Loreth; Synnöve Staff; Minna Tanner; Harriet Wikman; Timo Ylikomi
Journal:  Biomedicines       Date:  2022-01-26

7.  Interleukin-1 receptor-associated kinase-2 (IRAK2) is a critical mediator of endoplasmic reticulum (ER) stress signaling.

Authors:  Samir Benosman; Palaniyandi Ravanan; Ricardo G Correa; Ying-Chen Hou; Minjia Yu; Muhammet Fatih Gulen; Xiaoxia Li; James Thomas; Michael Cuddy; Yasuko Matsuzawa; Renata Sano; Paul Diaz; Shu-ichi Matsuzawa; John C Reed
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

8.  The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells.

Authors:  Reema A Ishteiwy; Toby M Ward; Derek M Dykxhoorn; Kerry L Burnstein
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

9.  The ghosts of HeLa: How cell line misidentification contaminates the scientific literature.

Authors:  Serge P J M Horbach; Willem Halffman
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

Review 10.  Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells.

Authors:  Takeshi Namekawa; Kazuhiro Ikeda; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Cells       Date:  2019-01-20       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.